Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Skye Bioscience, Inc. (NASDAQ: SKYE) between Nov. 2024 and Oct. 2025 should contact the Shareholders Foundation

Core Viewpoint - Skye Bioscience, Inc. is facing legal action from investors following the failure of its clinical trial for nimacimab, which did not meet its primary endpoint for weight loss compared to placebo [4]. Group 1: Legal Action - A lawsuit has been filed against Skye Bioscience, Inc. by an investor alleging violations of securities laws, claiming that the company made false or misleading statements regarding the effectiveness of nimacimab [4]. - Investors who purchased over $100,000 in Skye Bioscience shares between November 4, 2024, and October 3, 2025, have a deadline of January 16, 2026, to take action [2]. Group 2: Clinical Trial Details - Skye Bioscience initiated the "CBeyond" clinical trial in August 2024, a 26-week study aimed at assessing nimacimab for obesity treatment, with a primary endpoint of an 8% difference in mean weight loss compared to placebo [3]. - On October 6, 2025, the company announced that the nimacimab monotherapy did not achieve the primary endpoint of weight loss compared to placebo, and preliminary analysis indicated lower than expected drug exposure [4].